197 related articles for article (PubMed ID: 20423339)
21. Ruthenium complex with benznidazole and nitric oxide as a new candidate for the treatment of chagas disease.
Sesti-Costa R; Carneiro ZA; Silva MC; Santos M; Silva GK; Milanezi C; da Silva RS; Silva JS
PLoS Negl Trop Dis; 2014 Oct; 8(10):e3207. PubMed ID: 25275456
[TBL] [Abstract][Full Text] [Related]
22. Phenothiazinium Dyes Are Active against
Bulhões Portapilla G; Pereira LM; Bronzon da Costa CM; Voltarelli Providello M; Sampaio Oliveira PA; Goulart A; Ferreira Anchieta N; Wainwright M; Leite Braga GÚ; de Albuquerque S
Biomed Res Int; 2019; 2019():8301569. PubMed ID: 31355283
[TBL] [Abstract][Full Text] [Related]
23. Antitrypanosomal therapy for chronic Chagas' disease.
Bern C
N Engl J Med; 2011 Jun; 364(26):2527-34. PubMed ID: 21714649
[No Abstract] [Full Text] [Related]
24. Current status of Chagas disease chemotherapy.
Guedes PM; Silva GK; Gutierrez FR; Silva JS
Expert Rev Anti Infect Ther; 2011 May; 9(5):609-20. PubMed ID: 21609270
[TBL] [Abstract][Full Text] [Related]
25. In vitro and in vivo trypanocidal effects of the cyclopalladated compound 7a, a drug candidate for treatment of Chagas' disease.
Matsuo AL; Silva LS; Torrecilhas AC; Pascoalino BS; Ramos TC; Rodrigues EG; Schenkman S; Caires AC; Travassos LR
Antimicrob Agents Chemother; 2010 Aug; 54(8):3318-25. PubMed ID: 20479201
[TBL] [Abstract][Full Text] [Related]
26. New drug discovery strategies for the treatment of benznidazole-resistance in
Murta SMF; Lemos Santana PA; Jacques Dit Lapierre TJW; Penteado AB; El Hajje M; Navarro Vinha TC; Liarte DB; de Souza ML; Goulart Trossini GH; de Oliveira Rezende Júnior C; de Oliveira RB; Ferreira RS
Expert Opin Drug Discov; 2024 Jun; 19(6):741-753. PubMed ID: 38715393
[TBL] [Abstract][Full Text] [Related]
27. [Chagas' disease: clastogenic effect of nifurtimox and benznidazole in children].
Moya PR; Trombotto GT
Medicina (B Aires); 1988; 48(5):487-91. PubMed ID: 3151216
[No Abstract] [Full Text] [Related]
28. Antitrypanosomal agents: treatment or threat?
Issa VS; Bocchi EA
Lancet; 2010 Sep; 376(9743):768; author reply 768-9. PubMed ID: 20816538
[No Abstract] [Full Text] [Related]
29. Trypanocidal activity of 4 isopropyl salicylaldehyde and 4-isopropyl salicylic acid on Trypanosoma cruzi.
Nogueda-Torres B; Rodríguez-Paez L; Ramírez IB; Ramírez CW
Rev Latinoam Microbiol; 2001; 43(1):1-6. PubMed ID: 17061565
[TBL] [Abstract][Full Text] [Related]
30. Effects of buthionine sulfoximine nifurtimox and benznidazole upon trypanothione and metallothionein proteins in Trypanosoma cruzi.
Maya JD; Rodríguez A; Pino L; Pabón A; Ferreira J; Pavani M; Repetto Y; Morello A
Biol Res; 2004; 37(1):61-9. PubMed ID: 15174306
[TBL] [Abstract][Full Text] [Related]
31. Potential new clinical therapies for Chagas disease.
Bustamante JM; Tarleton RL
Expert Rev Clin Pharmacol; 2014 May; 7(3):317-25. PubMed ID: 24716790
[TBL] [Abstract][Full Text] [Related]
32. Repurposing strategies for Chagas disease therapy: the effect of imatinib and derivatives against Trypanosoma cruzi.
Simões-Silva MR; De Araújo JS; Peres RB; Da Silva PB; Batista MM; De Azevedo LD; Bastos MM; Bahia MT; Boechat N; Soeiro MNC
Parasitology; 2019 Jul; 146(8):1006-1012. PubMed ID: 30859917
[TBL] [Abstract][Full Text] [Related]
33. Drug discovery for chagas disease: A viewpoint.
Kratz JM
Acta Trop; 2019 Oct; 198():105107. PubMed ID: 31351074
[TBL] [Abstract][Full Text] [Related]
34. New 1,2,3-triazole-based analogues of benznidazole for use against Trypanosoma cruzi infection: In vitro and in vivo evaluations.
Leite DI; Fontes FV; Bastos MM; Hoelz LVB; Bianco MDCAD; de Oliveira AP; da Silva PB; da Silva CF; Batista DDGJ; da Gama ANS; Peres RB; Villar JDF; Soeiro MNC; Boechat N
Chem Biol Drug Des; 2018 Sep; 92(3):1670-1682. PubMed ID: 29745048
[TBL] [Abstract][Full Text] [Related]
35. Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas' disease drug discovery.
MacLean LM; Thomas J; Lewis MD; Cotillo I; Gray DW; De Rycker M
PLoS Negl Trop Dis; 2018 Jul; 12(7):e0006612. PubMed ID: 30001347
[TBL] [Abstract][Full Text] [Related]
36. Antiprotozoal drug nitazoxanide enhances parasitemia, tissue lesions and mortality caused by Trypanosoma cruzi in murine model.
Valle-Reyes JS; Melnikov V; Dobrovinskaya O; Rodriguez-Hernández A; Wookee-Zea C; Pimientel-Rodrigez V; Rueda-Valdovinos G; Delgado-Enciso I; López-Lemus UA; Espinoza-Gómez F
Exp Parasitol; 2017 Jan; 172():44-50. PubMed ID: 28011170
[TBL] [Abstract][Full Text] [Related]
37. [Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas' disease, in a field area with interrupted transmission. I. Preliminary evaluation].
Coura JR; de Abreu LL; Willcox HP; Petana W
Rev Soc Bras Med Trop; 1997; 30(2):139-44. PubMed ID: 9148337
[TBL] [Abstract][Full Text] [Related]
38. The challenge of Chagas' disease chemotherapy: an update of drugs assayed against Trypanosoma cruzi.
de Castro SL
Acta Trop; 1993 Apr; 53(2):83-98. PubMed ID: 8098901
[TBL] [Abstract][Full Text] [Related]
39. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host.
Maya JD; Cassels BK; Iturriaga-Vásquez P; Ferreira J; Faúndez M; Galanti N; Ferreira A; Morello A
Comp Biochem Physiol A Mol Integr Physiol; 2007 Apr; 146(4):601-20. PubMed ID: 16626984
[TBL] [Abstract][Full Text] [Related]
40. Trypanosoma cruzi: In vitro effect of aspirin with nifurtimox and benznidazole.
López-Muñoz R; Faúndez M; Klein S; Escanilla S; Torres G; Lee-Liu D; Ferreira J; Kemmerling U; Orellana M; Morello A; Ferreira A; Maya JD
Exp Parasitol; 2010 Feb; 124(2):167-71. PubMed ID: 19735656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
